Ganciclovir pharmacokinetics during renal impairment

K. D. Lake, C. V. Fletcher, K. R. Love, D. C. Brown, L. D. Joyce, M. R. Pritzker

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Limited information is available concerning the use of ganciclovir (GCV) in patients with severe renal impairment. The pharmacokinetics of GCV were studied in a heart transplant recipient requiring hemodialysis. The total body clearance was calculated to be approximately 5% of that previously reported for patients with normal renal function. GCV was removed by hemodialysis; a single 4-h procedure decreased the concentration in plasma by approximately 50%. GCV can be safely administered to patients with renal insufficiency if concentrations in plasma are monitored.

Original languageEnglish (US)
Pages (from-to)1899-1900
Number of pages2
JournalAntimicrobial agents and chemotherapy
Volume32
Issue number12
DOIs
StatePublished - 1988

Fingerprint Dive into the research topics of 'Ganciclovir pharmacokinetics during renal impairment'. Together they form a unique fingerprint.

Cite this